Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
This article was originally published in PharmAsia News
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
You may also be interested in...
With Roche’s Pascal Soriot set to become AstraZeneca’s CEO on Oct. 1, Soriot’s success in merging Genentech into Roche may open up AZ’s business development strategy to large-scale M&A.
The Indian company has sold most of its injectables business to industry leader Hospira. What it does next to grow is a big question.
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan